Global /China /Industrials /Specialty Business Services /300725
chevron_leftBack
PharmaBlock Sciences (Nanjing), Inc. logo

PharmaBlock Sciences (Nanjing), Inc.

300725
SHE: 300725 Delayed
39.85CNY -0.4%
5.89 USD
As of 5 June 2026, PharmaBlock Sciences (Nanjing), Inc. has a market cap of $1.38B USD, ranking #8929 globally and #2366 in China. It ranks #1961 in the Industrials sector, and #173 in the Specialty Business Services industry.
Global Rank
8929
Country Rank
2366
Sector Rank
1961
Industry Rank
173
Key Stats
Market Cap
$1.38BUSD
9.32B CNY
Enterprise Value
$1.24BUSD
8.37B CNY
Revenue (TTM)
$299.5MUSD
2.03B CNY
EBITDA (TTM)
$59.8MUSD
404.84M CNY
Net Income (TTM)
$29.08MUSD
196.83M CNY
EBITDA Margin
20%
Profit Margin
9.7%
PE Ratio
44.2
Forward PE
40.0
PS Ratio
4.6
PB Ratio
1.7
EV/EBITDA
20.5
Company Profile
Country (HQ)
Sector
Industrials
Industry
Specialty Business Services
CEO
Minmin Yang open_in_new
Employees
2,400
Founded
2006
Website
pharmablock.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-0.4% 3.5% 11% -4.8% -5.1% 24%

News

Loading...

Markets

Exchange Ticker Price
Shenzhen Stock Exchange
MIC: XSHE
PRIMARY
300725
南京药石科技股份有限公司 Class A
ISIN: CNE1000035K5
Shares Out.:
232.971M1 Shares Float: 197.227M2
TV:
SA:
YF:
GF:
BA:
MS:
39.85 CNY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About PharmaBlock Sciences (Nanjing), Inc.

PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, DNA encoded library technology, and mega virtual library screening to support the discovery of novel hit compounds; custom synthesis (FFS); and full time equivalent (FTE). The company also provides small molecule drug substance CDMO services, including optimal route scouting; FFS and FTE for process research and development of RSMs, intermediates, and APIs; impurity studies and synthesis; solid state chemistry; analytical development and quality control; cGMP manufacturing of intermediates and APIs; and CMC regulatory filing support. In addition, it offers small molecule DP CDMO services, such as candidate screening and selection, early development, full development, registration, and post-approval; and new modality services, including target protein degrader, peptide, oligonucleotide, and ADC services. PharmaBlock Sciences (Nanjing), Inc. was founded in 2006 and is based in Nanjing, the People's Republic of China.

Similar Companies

Industry: Specialty Business Services (China)
Name
Market Cap diff.
PE
$9.42B
73.79B HKD
584%
47.0
$8.77B
59.36B CNY
537%
296.1
$6.6B
379%
11.8
$6.25B
42.34B CNY
354%
480.6
$4.62B
31.29B CNY
236%
128.4
$4.6B
31.16B CNY
234%
163.3
Industry: Specialty Business Services (Global)
Name
Market Cap diff.
PE
SHOP
$158.14B
11K%
129.8
VSURE
$133.15B
114.8B EUR
10K%
-
CTAS
$69.6B
5K%
36.8
REL
$63.87B
47.6B GBP
5K%
23.9
PYPL
$45.83B
3K%
9.4
$41.8B
56.91B CAD
3K%
-
chevron_leftBack